peoplePerson
Timothy A. Chan
Timothy Chan showed that tumour mutational burden predicts who benefits from checkpoint inhibitors.
Physician-scientist whose 2014 and 2015 genomic studies linked mutational load and neoantigens to response to CTLA-4 and PD-1 blockade, and who showed HLA diversity shapes immunotherapy benefit.
Role
Director, Global Center for Immunotherapy; Chair, Center for Immunotherapy and Precision Immuno-Oncology
Institution
Specialisms
ImmunogenomicsTumour mutational burdenHLA and immunotherapy response
Profiles
| Title | Journal | Year |
|---|---|---|
| Genetic basis for clinical response to CTLA-4 blockade in melanoma | New England Journal of Medicine | 2014 |
| Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Science | 2015 |